Community Acquired Bacterial Pneumonia (CABP) Treatment Market
Community Acquired Bacterial Pneumonia (CABP) Treatment Market by Drug Class, Dose Form, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Market Insights on Community Acquired Bacterial Pneumonia (CABP) Treatment covering sales outlook, demand forecast and up-to-date key trends
Community Acquired Bacterial Pneumonia (CABP) Treatment Market Snapshot (2023 to 2033)
The global community acquired bacterial pneumonia (CABP) treatment market is expected to garner a market value of US$ 5 billion in 2023 and is expected to accumulate a market value of US$ 8.38 billion by registering a CAGR of 5.3% in the forecast period 2023 to 2033. The market for community acquired bacterial pneumonia (CABP) treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.
The market for community acquired bacterial pneumonia (CABP) treatment is expected to experience steady growth in the coming years, driven by several factors. CABP is a type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The global CABP treatment market includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections. The market is expected to be driven by an increase in the incidence of CABP, an aging population, and the development of new and innovative drugs to treat the condition.
Report Attribute
Details
Expected Market Value (2023)
US$ 5 Billion
Anticipated Forecast Value (2033)
US$ 8.38 Billion
Projected Growth Rate (2023 to 2033)
5.3% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Community Acquired Bacterial Pneumonia (CABP) Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for community acquired bacterial pneumonia (CABP) treatment reflected a value of 3.2% during the historical period, 2018 to 2022. The incidence of CABP is increasing globally, driven by factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. This has led to an increase in demand for CABP treatment, driving the growth of the market.
Key players in the market are focused on developing new and innovative drugs to treat CABP, which is expected to drive the growth of the market. The availability of effective antibiotics is also expected to contribute to the growth of the market. Furthermore, Increasing healthcare spending in developing countries is expected to drive the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the large population and increasing healthcare spending in countries such as India and China.
Overall, the market for community acquired bacterial pneumonia (CABP) treatment is expected to register a CAGR of 5.3% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Community Acquired Bacterial Pneumonia (CABP) Treatment Market?
Increasing Prevalence of Community Acquired Bacterial Pneumonia (CABP) to push market growth
An increase in the incidence of Community Acquired Bacterial Pneumonia (CABP) is expected to drive the growth of the CABP treatment market. CABP is a common type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The incidence of CABP is increasing globally due to factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. According to studies, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In addition to this, approximately 650 adults are hospitalized with CAP every year per 100,000 population in the United States, corresponding to 1.5 million unique CAP hospitalizations each year. As the incidence of CABP increases, the demand for CABP treatment is also expected to increase, which is likely to drive the growth of the market.
Moreover, the availability of effective antibiotics and the development of new and innovative drugs to treat CABP are also expected to contribute to the growth of the market.
In addition to these factors, increasing healthcare spending in developing countries and the presence of advanced healthcare infrastructure in developed regions are also expected to drive the growth of the CABP treatment market. Overall, the CABP treatment market is expected to experience steady growth in the coming years, driven by an increase in the incidence of CABP and other factors.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by Community Acquired Bacterial Pneumonia (CABP) Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for community acquired bacterial pneumonia (CABP) can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.
Additionally, despite increasing awareness of Community Acquired Bacterial Pneumonia (CABP), there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.
Moreover, the regulatory requirements for approval of new treatments for Community Acquired Bacterial Pneumonia (CABP) can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.
Region-Wise Insights
How is the Community Acquired Bacterial Pneumonia (CABP) Treatment Market Turning Out in the South & East Asia Region?
Increasing awareness and diagnosis of the condition Shaping Landscape for CABP Treatment in South & East Asia
The South and East Asia region is a growing market for community acquired bacterial pneumonia (CABP) treatment. The region includes countries such as India, China, Japan, South Korea, and the ASEAN countries. The market is driven by the increasing prevalence of CABP and the growing demand for effective treatments in the region.
This growth can be attributed to factors such as the increasing aging population, high burden of respiratory diseases, and increasing healthcare spending in countries such as India and China.
In India, the prevalence of CABP is high, especially among the elderly and immunocompromised populations. The market is witnessing the entry of new players, including local and international pharmaceutical companies, which is expected to increase competition and innovation in the market.
In China, the prevalence of CABP is also high, driven by factors such as air pollution, smoking, and an aging population. The government is taking steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to drive the growth of the market.
Overall, the CABP treatment market in the South and East Asia region is turning out to be a promising market with significant growth potential. The increasing prevalence of CABP and the growing demand for effective treatments are expected to drive the growth of the market in the region in the coming years.
What are the Factors Boosting the Market for Community Acquired Bacterial Pneumonia (CABP) Treatment in North America?
Increasing Focus on Technological Advancements Shaping Landscape for CABP Treatment in North America
The incidence of CABP is high in North America, particularly in the elderly and immunocompromised populations. This has led to a high demand for effective CABP treatments in the region. North America has a significant pipeline of new antibiotics under development for the treatment of CABP. This has led to the availability of new and effective treatments, which is expected to drive the growth of the market.
Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. This has helped to support the development and adoption of new treatments for Community Acquired Bacterial Pneumonia (CABP).
Overall, these factors are driving the growth of the Community Acquired Bacterial Pneumonia (CABP) Treatment market in North America. However, there are still challenges facing the market, including high treatment costs and the need for more effective and targeted therapies. Nonetheless, the market is expected to continue growing as new treatments and technologies are developed and as the awareness of community acquired bacterial pneumonia (CABP) continues to increase.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Route of Administration, Which Segment is Likely to Account for a Significant Share?
Intravenous (IV) route of administration to hold a significant share and push market growth
Among the different treatments for community acquired bacterial pneumonia (CABP), the intravenous (IV) route of administration is likely to account for a significant share of the market.
This is because IV antibiotics are often the first-line treatment for severe cases of CABP, where prompt and effective treatment is critical for improving patient outcomes. IV antibiotics can rapidly achieve therapeutic levels in the bloodstream, leading to a faster resolution of symptoms and a shorter hospital stay.
Additionally, IV antibiotics can be administered in a hospital or outpatient setting, depending on the severity of the illness, which adds to the convenience of treatment for patients.
Overall, while the IV route of administration is likely to account for a significant share of the CABP treatment market, the inhaled route of administration is an emerging segment that is expected to gain traction in the coming years.
By Distribution Channel, Which Segment is Likely to Account for a Significant Share?
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies play a critical role in the management of CABP, as they are often the first point of contact for patients with CABP. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of CABP.
In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with CABP. This team-based approach is critical for the management of CABP, as it allows for individualized treatment plans that address the unique needs of each patient
Market Competition
Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.
The USA Food and Drug Administration granted approval for Xenleta (lefamulin) to treat adults suffering from community-acquired bacterial pneumonia. This new drug provides an additional treatment option for patients with this serious illness, which can range in severity from mild to severe and affect people of all ages.
According to the Centers for Disease Control and Prevention, about one million people in the United States are hospitalized with community-acquired pneumonia each year, and approximately 50,000 individuals succumb to the disease. Dr. Ed Cox, Director of FDA’s Office of Antimicrobial Products, stated that the approval of Xenleta is a significant step in facilitating the development of new antibiotics and addressing the treatment of infectious diseases.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 5 billion
Market Value in 2033
US$ 8.38 billion
Growth Rate
CAGR of 5.3% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Route of Administration
Dose Form
Drug Class
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Nabriva Therapeutics
Melinta Therapeutics
Wakunaga Pharmaceutical Co. Ltd.
Actavis Generics
Pfizer Inc.
Paratek Pharmaceuticals
Cumberland Pharmaceuticals Inc.
Theravance Biopharma Inc.
Merck Sharp & Dohme Inc.
Cubist Pharmaceuticals LLC (Merck)
Shionogi Inc.
Allergan Plc.
Eagle Pharmaceuticals Inc.
Combioxin
TiGenix
Customization
Available Upon Request
Key Segments Profiled in the Community Acquired Bacterial Pneumonia (CABP) Treatment Industry Survey
Dose Form:
Solution
Tablet
Drug Class:
Pleuromutilin
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Route of Administration:
Oral
Intravenous
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the Current Market Size of CABP?
In 2023, the market may potentially be worth US$ 5 billion.
What is the Estimated Market Growth From 2023 to 2033?
The market may steadily transform at a CAGR of 5.3% through 2033.
How was the Past Performance of the Market?
The market registered a HCAGR of 3.2 between 2018 and 2022.
What will the Market Size of CABP in 2033?
The estimated value of the global market in 2033 is US$ 8.38 billion.
Which Distribution Channel Segment is Forecast to Hold a Strong Share?
Hospital pharmacies are poised to capture a considerable market share.
Table of Content
1. Executive Summary | Community Acquired Bacterial Pneumonia (CABP) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Pleuromutilin
5.3.2. Cephalosporin
5.3.3. Glycylcycline
5.3.4. Oxazolidinone
5.3.5. Ketolide
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dose Form
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dose Form, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dose Form, 2023 to 2033
6.3.1. Solution
6.3.2. Tablet
6.4. Y-o-Y Growth Trend Analysis By Dose Form, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dose Form, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
7.3.1. Oral
7.3.2. Intravenous
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Dose Form
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Dose Form
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Dose Form
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Dose Form
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Dose Form
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Dose Form
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Dose Form
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Dose Form
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Dose Form
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Dose Form
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Dose Form
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Dose Form
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Dose Form
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Dose Form
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Dose Form
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Dose Form
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Dose Form
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Dose Form
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Dose Form
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Dose Form
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Dose Form
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Dose Form
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Dose Form
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Dose Form
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Dose Form
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Dose Form
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Dose Form
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Dose Form
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Dose Form
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Dose Form
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Dose Form
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Dose Form
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Dose Form
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Dose Form
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Dose Form
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Dose Form
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Nabriva Therapeutics
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Melinta Therapeutics
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Wakunaga Pharmaceutical Co. Ltd.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Actavis Generics
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pfizer
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Paratek Pharmaceuticals
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Cumberland Pharmaceuticals Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Theravance Biopharma Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Merck Sharp & Dohme Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Cubist Pharmaceuticals LLC (Merck)
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Shionogi Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Allergan Plc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Eagle Pharmaceutical Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Combioxin
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Takeda
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.16. TiGenix
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: South Asia Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 24: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 25: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 29: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 33: Oceania Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 34: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 35: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 38: MEA Market Value (US$ Million) Forecast by Dose Form, 2018 to 2033
Table 39: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 22: Global Market Attractiveness by Dose Form, 2023 to 2033
Figure 23: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 47: North America Market Attractiveness by Dose Form, 2023 to 2033
Figure 48: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Dose Form, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 97: Europe Market Attractiveness by Dose Form, 2023 to 2033
Figure 98: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: South Asia Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 103: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 104: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 112: South Asia Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 115: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 118: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 122: South Asia Market Attractiveness by Dose Form, 2023 to 2033
Figure 123: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 127: East Asia Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 129: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 137: East Asia Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 140: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 143: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 147: East Asia Market Attractiveness by Dose Form, 2023 to 2033
Figure 148: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 152: Oceania Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 153: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 154: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 162: Oceania Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 165: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 168: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 172: Oceania Market Attractiveness by Dose Form, 2023 to 2033
Figure 173: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 177: MEA Market Value (US$ Million) by Dose Form, 2023 to 2033
Figure 178: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 187: MEA Market Value (US$ Million) Analysis by Dose Form, 2018 to 2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Dose Form, 2023 to 2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Dose Form, 2023 to 2033
Figure 190: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 197: MEA Market Attractiveness by Dose Form, 2023 to 2033
Figure 198: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
